Pennsaid 2%

Topical pain product – Combines a dimethyl sulfoxide (DMSO) based transdermal carrier with 2% diclofenac sodium, a leading NSAID

Indication

  • Treating the pain of osteoarthritis of the knee

Benefits

  • Low systemic exposure to minimize side effects
  • First twice per day dosing topical NSAID in the U.S.
  • Metered dose dispenser

Commercial Status

  • Marketed in the U.S. by Horizon Pharma plc – January 2015

Intellectual Property

  • Patents issued in nineteen countries (ex-U.S.) and pending in four countries with the latest expiring 2027
  • Pennsaid Pump patent issued in Russia expiring 2033; applications pending in nine countries through 2033

Website